ArticleGeroScience2026
Frailty and major late-life transitions in very old adults: contrasting biomarker patterns of GDF-15 and NT-proBNP in the Kawasaki Aging and Wellbeing Project.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Frailty is a heterogeneous aging phenotype that represents accumulated biological vulnerability among very old adults. How frailty relates to key late-life transitions at advanced ages remains incompletely understood. We examined the longitudinal association between frailty status and a composite endpoint of incident long-term care insurance certification (level ≥ 2) or death, and assessed whether circulating biomarkers (growth differentiation factor-15 [GDF-15] and N-terminal pro-B-type natriuretic peptide [NT-proBNP]) provided information beyond frailty. In this cohort study, 992 community-dwelling adults aged 85-89 years in Japan, classified using physical frailty criteria at baseline as either robust, prefrail, or frail, were followed up to 7.5 years. Risk over time was compared using Kaplan-Meier methods, and Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs). Kaplan-Meier curves showed clear separation across the frailty groups. In multivariable models, prefrail and frail status were associated with a higher risk of the composite endpoint (aHRs 1.62 and 2.13 vs. robust, respectively). After adjusting for frailty status and covariates, higher GDF-15 and NT-proBNP levels were independently associated with greater risk. The GDF-15 association was adequately described by a linear term, whereas NT-proBNP showed evidence of nonlinearity with a steeper gradient toward the upper range. As a supportive summary of risk stratification, 5-year discrimination changed only modestly after adding biomarkers. Frailty strongly stratified the risk of major late-life transitions, and baseline GDF-15 and NT-proBNP may help characterize residual biological heterogeneity beyond frailty, with contrasting dose-response patterns.
Indexed as
Identifiers
42307835What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.